| A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening ML Beshiri, CM Tice, C Tran, HM Nguyen, AG Sowalsky, S Agarwal, ... Clinical Cancer Research 24 (17), 4332-4345, 2018 | 176 | 2018 |
| EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis L Li, AH Ameri, S Wang, KH Jansson, OM Casey, Q Yang, ML Beshiri, ... Oncogene 38 (35), 6241-6255, 2019 | 106 | 2019 |
| Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ... Nature communications 12 (1), 1979, 2021 | 88 | 2021 |
| Identification of different classes of luminal progenitor cells within prostate tumors S Agarwal, PG Hynes, HS Tillman, R Lake, WG Abou-Kheir, L Fang, ... Cell reports 13 (10), 2147-2158, 2015 | 58 | 2015 |
| NOTCH3 is a prognostic factor that promotes glioma cell proliferation, migration and invasion via activation of CCND1 and EGFR MAY Alqudah, S Agarwal, MS Al-Keilani, ZA Sibenaller, TC Ryken, ... PloS one 8 (10), e77299, 2013 | 57 | 2013 |
| Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor R Adelaiye-Ogala, BE Gryder, YTM Nguyen, AN Alilin, AR Grayson, ... Molecular cancer therapeutics 19 (7), 1436-1447, 2020 | 40 | 2020 |
| High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer KH Jansson, JB Tucker, LE Stahl, JK Simmons, C Fuller, ML Beshiri, ... Scientific Reports 8 (1), 17239, 2018 | 32 | 2018 |
| Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics M Assem, Z Sibenaller, S Agarwal, MS Al-Keilani, MAY Alqudah, ... OMICS: A Journal of Integrative Biology 16 (3), 113-122, 2012 | 30 | 2012 |
| Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma S Agarwal, MS Al-Keilani, MAY Alqudah, ZA Sibenaller, TC Ryken, ... PloS one 8 (5), e62852, 2013 | 29 | 2013 |
| Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer H Pan, KH Jansson, ML Beshiri, JJ Yin, L Fang, S Agarwal, H Nguyen, ... Oncotarget 8 (44), 77181, 2017 | 28 | 2017 |
| Prostate organoids: emerging experimental tools for translational research M Beshiri, S Agarwal, JJ Yin, K Kelly The Journal of Clinical Investigation 133 (10), 2023 | 7 | 2023 |
| Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A NC Whitlock, ME White, BJ Capaldo, AT Ku, S Agarwal, L Fang, ... Discover Oncology 13 (1), 97, 2022 | 3 | 2022 |
| Reprogramming of the FOXA1 cistrome in treatmentemergent neuroendocrine prostate cancer. bioRxiv SC Baca, DY Takeda, JH Seo Published online October 24, 2020.10, 2020 | 3 | 2020 |
| Tyrosyl DNA phosphodiesterase I is a prognostic factor and its inhibition synergizes response to topoisomerase poisons in malignant glioma. M Al-Keilani, S Agarwal, M Alqudah, Z Sibenaller, T Ryken, M Assem Cancer Research 73 (8_Supplement), 2194-2194, 2013 | 2 | 2013 |
| Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models S Agarwal, L Fang, K McGowen, JJ Yin, J Bowman, AT Ku, AN Alilin, ... The Journal of Clinical Investigation 133 (22), 2023 | 1 | 2023 |
| A CD276/B7H3 targeted antibody drug conjugate is efficacious across multiple biomarker defined classes of metastatic prostate cancer S Agarwal, L Fang, K McGowen, J Yin, J Bowman, AT Ku, AN Alilin, ... | 1 | 2022 |
| A cancer stem cell population underlies a multi-lineage phenotype and drug resistance in prostate cancer ML Beshiri, BJ Capaldo, R Lake, AT Ku, D Burner, CM Tice, C Tran, ... | 1 | 2022 |
| Protein tyrosine phosphatase receptor type kappa is a glioma tumor suppressor that predicts survival and response to therapy S Agarwal University of Iowa, 2013 | 1 | 2013 |
| Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer ML Beshiri, BJ Capaldo, R Lake, AT Ku, D Burner, CM Tice, C Tran, ... Stem Cells, sxae025, 2024 | | 2024 |
| Metabolic and imaging phenotypes associated with RB1 loss in castrate resistant prostate cancer F Ahmad, M White, K Yamamoto, DR Crooks, S Agarwal, Y Yang, ... bioRxiv, 2023.11. 15.567250, 2023 | | 2023 |
